Independent · UK · Updated for 2026

The UK's plain-English guide to Mounjaro, Wegovy, the Wegovy pill and Ozempic.

Updated

No hype, no sales pitch, no jargon. Careful guides, honest calculators and official UK sources, written for real people making real decisions about GLP-1 medicines.

Checked against NHS, NICE, MHRA & GPhC sources STEP, SURMOUNT, OASIS & SELECT trials cited We never sell or prescribe medicines
20.9%

Average weight loss on tirzepatide 15 mg in SURMOUNT-1

20%

Cut in heart attacks and strokes on semaglutide 2.4 mg (SELECT)

16.6%

Average loss on the new Wegovy pill at full dose (OASIS 4)

60

Clicks in every full UK Mounjaro KwikPen dose, at any strength

Who runs this site?

Independent. Human-reviewed. Never a pharmacy.

GLP1Guide.co.uk is an independent editorial project. We don't prescribe or dispense, and we never will. The medical content stands on its own against NICE, NHS, MHRA and GPhC sources, and our funding model is documented openly on the about page.

Our standards

Editorial policy

Sourcing hierarchy, human review, update schedule and corrections. Documented in full.

Read it →

References & official sources

Show all 5 cited sources, with study authors +
  1. NICE TA1026. Tirzepatide for managing overweight and obesity: www.nice.org.uk/guidance/ta1026
  2. NICE TA875. Semaglutide for managing overweight and obesity: www.nice.org.uk/guidance/ta875
  3. NHS England. Interim commissioning guidance for tirzepatide (Mounjaro): www.england.nhs.uk/long-read/interim-commissioning-guidance-nice-ta1026-tirzepatide/
  4. MHRA. Yellow Card reporting scheme: yellowcard.mhra.gov.uk/
  5. GPhC. Check a pharmacy registration: www.pharmacyregulation.org/registers
Remember: this page is general education for UK readers, not personal medical advice. Mounjaro, Wegovy and Ozempic are prescription-only medicines. Your prescriber and pharmacist know your history, so their guidance always comes first. Spot a side effect? Report it via the MHRA Yellow Card scheme.